– Total Revenues increased 21.3% for the quarter over the prior year period to $64.1 million –– Total Written Premium increased 16.9% for the quarter over the prior year period to $467.7 million –– Organic Revenue Growth Rate* of 10.2% for the quarter –– Net income of $9.6 million for the quarter –– Adjusted EBITDA* increased 44.7% for the quarter over the prior year period to $17.0 million – THE WOODLANDS, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- TWFG, Inc. (“TWFG”, the “Company” or “we”) (NASDAQ: TWFG), a ...

Core Insights - Ambac Financial Group, Inc. reported a significant organic revenue growth of 40% in its Insurance Distribution segment, contributing to an overall revenue increase of 80% to $43 million for the quarter compared to $24 million in Q3'24 [1] Financial Performance - The Insurance Distribution segment recorded a net loss to shareholders of $5 million for the quarter, an improvement from a net loss of $7 million in Q3'24 [2] - Adjusted EBITDA for the Insurance Distribution segment surged by 272% to $10 million, up from $2.4 million in Q3'24, while adjusted EBITDA to shareholders increased by 183% to $6 million from $2.1 million [2] - Total revenues from continuing operations dipped by 5% to $67 million in Q3'25, down from $70 million in Q3'24, primarily due to reduced earned premiums at Everspan and the impact of previous gains [3][4] - Everspan's gross and net premiums written decreased by 16% and 46%, respectively, totaling $97.1 million and $18 million compared to $115 million and $32.7 million in Q3'24 [4] - The net loss to shareholders from continuing operations increased by $14 million to $32 million in Q3'25, compared to $18 million last year [4] Expense Analysis - Total expenses rose by 9% to $99 million in Q3'25 from $91 million the previous year, driven by increases in G&A expenses, intangible amortization, and interest expenses related to acquisitions [5] - G&A expenses included costs associated with exiting the financial guarantee business and the acquisition of ArmadaCare, which offset lower nominal losses and acquisition expenses at Everspan [6] Strategic Developments - Adjusted EBITDA from continuing operations to Ambac shareholders was a loss of $3 million in Q3'25, compared to a gain of $2 million last year, influenced by lower adjusted EBITDA at Everspan and expenses related to M&A and legacy litigation [7] - The company repurchased 3.1 million shares in October at an average price of $8.48, representing 6.7% of shares outstanding [8] - The CEO emphasized the focus on growth and profitability in specialty P&C businesses following the sale of the legacy financial guarantee business, highlighting strong performance in the insurance distribution segment [8] - The company anticipates improved combined ratios for Everspan as it scales between 2026 and 2027 and is optimistic about future prospects, reinforced by share repurchases [9] - Ambac expanded its partnership with Pivix and announced the launch of 1889 Specialty, a new MGA venture, indicating strategic growth initiatives [9]

Core Insights - JCDecaux SE reported a Q3 2025 revenue of €926.1 million, reflecting a -2.3% decrease compared to Q3 2024, with organic growth down by -0.9% [6][12][20] - The company secured a significant contract for exclusive advertising at Brussels Airport, effective January 1, 2026, which had 23.6 million passengers in 2024 [3][4] - Digital Out-of-Home (DOOH) revenue grew by +6.1%, now representing 41.8% of total revenue, with programmatic revenue increasing by +12.3% [6][12] Revenue Breakdown - Street Furniture revenue decreased by -2.5% to €456.9 million, with a -1.1% decline in organic growth, primarily due to a high comparison base from 2024 [14][15] - Transport revenue slightly decreased by -0.4% to €345.5 million, but showed a +1.7% organic growth driven by North America and Rest of the World [17] - Billboard revenue fell by -6.8% to €123.7 million, with a -6.9% decline in organic growth, largely affected by a strong comparison base in France [18] Future Outlook - For Q4 2025, the company anticipates organic revenue growth to be around flat, with advertising revenue expected to increase by approximately +1% [20][9] - The macroeconomic environment remains challenging, particularly with no expected improvement in trading conditions in China [20][9]

Second Quarter Fiscal 2026 Results November 6, 2025 © 2025 Haemonetics Corporation Q2 Fiscal 2026 Conference Call Detail Conference call will take place at 8:00 a.m. ET on November 6, 2025, and can be accessed via live webcast: Link or teleconference: Link The financial release, accompanying slides, and a replay of the conference call (beginning at 11:00 AM ET) are available online at www.haemonetics.com. Conference call speakers: Chris Simon President & CEO James D'Arecca EVP, Chief Financial Officer Olga ...

Core Insights - Aon plc reported third-quarter 2025 adjusted earnings of $3.05 per share, exceeding the Zacks Consensus Estimate by 5.5%, with a 12% increase year-over-year [1][10] - Total revenues rose 7% year-over-year to $4 billion, surpassing the consensus mark by 1.4%, driven by new business growth and strong retention rates [1][10] - Organic revenue growth was recorded at 7% [1] Financial Performance - Total operating expenses increased 3% year-over-year to $3.2 billion, influenced by organic revenue growth and increased intangible asset amortization [3] - Adjusted operating income advanced 15% year-over-year to $1.1 billion, beating estimates by 1.9%, with an adjusted operating margin of 26.3%, improving by 170 basis points [4] Segmental Performance - **Risk Capital**: - Commercial Risk Solutions saw organic revenues grow 7% year-over-year to $2 billion, exceeding the Zacks Consensus Estimate by 1.1% [5] - Reinsurance Solutions experienced an 8% organic revenue increase to $537 million, surpassing the consensus mark of $531.4 million [6] - **Human Capital**: - Health Solutions reported a 6% organic revenue growth, with revenues of $935 million, beating the Zacks Consensus Estimate of $927.4 million [7] - Wealth Solutions improved by 5% year-over-year, with revenues growing 8% to $540 million, exceeding the consensus mark of $524.4 million [8] Financial Position - As of September 30, 2025, Aon had cash and cash equivalents of $1.1 billion, a 0.9% increase from the end of 2024, and total assets of $51.6 billion, up from $49 billion [9] - Long-term debt decreased to $15.1 billion from $16.3 billion at the end of 2024, while cash flow from operations rose to $1.1 billion, up from $1 billion a year ago [11] Capital Deployment - Aon repurchased 0.7 million class A ordinary shares for approximately $250 million in the third quarter, with a remaining capacity of around $1.6 billion under its repurchase authorization [12] Forward Guidance - Aon expects mid-single-digit or higher organic revenue growth for 2025 and beyond, with anticipated expansion in adjusted operating margin and strong growth in adjusted EPS [13] - The Aon United Restructuring program is projected to achieve total annual run-rate savings of approximately $350 million by the end of 2026 [14]

Core Insights - Mondelez International, Inc. (MDLZ) reported third-quarter 2025 results with a year-over-year revenue increase, surpassing the Zacks Consensus Estimate, but a decline in adjusted earnings year over year, although still beating consensus expectations [1][12] Financial Performance - Net revenues rose 5.9% year over year to $9,744 million, exceeding the Zacks Consensus Estimate of $9,737 million, driven by organic net revenue growth, positive foreign currency impacts, and additional revenues from the acquisition of Evirth [4] - Adjusted earnings were 73 cents per share, a decrease of 24.2% on a constant-currency basis, but above the Zacks Consensus Estimate of 72 cents, primarily due to operating declines offset by lower taxes and fewer shares outstanding [5][12] - Organic net revenues grew 3.4% year over year, with pricing contributing 8.0 percentage points, while volume/mix had a negative impact of 4.6 percentage points [6] Market Segmentation - Revenues from emerging markets increased 9.9% to $3.88 billion, with organic growth of 7.1%, supported by favorable pricing actions [7] - Revenues from developed markets rose 3.3% to $5.86 billion, with organic growth of 1.2%, driven by strong pricing execution [7] - Regionally, North America saw a revenue decline of 0.4%, while Latin America, Asia, the Middle East and Africa, and Europe experienced growth of 2.8%, 9%, and 10.6% respectively [8] Cost and Margin Analysis - Adjusted gross profit decreased by $796 million at constant currency, with the adjusted gross margin declining by 1,010 basis points to 30.4%, primarily due to higher raw material and transportation costs [9] - Adjusted operating income fell by $582 million at constant currency, with the adjusted operating income margin declining by 690 basis points to 12%, driven by higher input cost inflation [10] Future Outlook - The company updated its 2025 outlook to reflect a more cautious stance, expecting organic net revenue growth of 4% or higher, down from the previous 5% estimate, and a projected 15% decline in adjusted EPS on a constant-currency basis [2][17] - Management anticipates free cash flow of more than $3 billion for 2025, with $2.12 billion in net cash from operating activities reported for the three months ended September 30, 2025 [13][17]

Financial Data and Key Metrics Changes - Total company operational sales grew 19% in Q3 2025, while organic sales increased by 15%, exceeding the guidance range of 12% to 14% [6][22] - Adjusted EPS for Q3 2025 was $0.75, reflecting a 19% growth and surpassing the guidance range of $0.70 to $0.72 [6][22] - Adjusted operating margin for Q3 was 28%, with an adjusted gross margin of 71%, showing a 60 basis point improvement year-over-year [23][6] Business Line Data and Key Metrics Changes - Urology sales grew 27% operationally and 5% organically, driven by international business and Global Stone Management [9] - Endoscopy experienced a 9% growth, with double-digit growth in key products [10] - Neuromodulation sales increased by 9%, supported by strong performance in the brain franchise [10] - Peripheral interventions sales grew 16% operationally and 6% organically, with low single-digit growth in arterial due to pricing pressures in China [11] Market Data and Key Metrics Changes - U.S. operational sales grew 27%, with strong performance across cardiovascular businesses, endoscopy, and neuromodulation [7] - Europe, Middle East, and Africa (EMEA) saw a 2% decline operationally due to specific headwinds, while Asia-Pacific grew 17% operationally [7][8] - China experienced mid-teens growth, driven by strong performance in electrophysiology and the recent approval of the Watchman Flex Pro device [8][9] Company Strategy and Development Direction - The company is focused on sustaining above-market growth, with a full-year 2025 organic growth guidance of approximately 15.5% [6][25] - The acquisition of Nalu Medical is expected to expand the company's portfolio into a new pain adjacency, complementing its existing strengths [11][81] - The company aims to achieve 10% plus average organic revenue growth from 2026 to 2028, along with annual adjusted operating margin expansion [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining growth despite challenges, with a focus on innovation and clinical evidence generation [20][39] - The company does not anticipate procedural pull-forwards due to external pressures, maintaining consistent procedural demand [38] - Management remains optimistic about the growth potential in the electrophysiology and Watchman markets, projecting a 20% CAGR over the long-range plan [33][48] Other Important Information - The company faced a $30 million backorder due to an ERP system upgrade, impacting various business lines but expected to improve in Q4 [7][75] - The company maintains a strong cash position with $1.275 billion on hand and a gross debt leverage ratio of 2.0 times [24] Q&A Session Summary Question: Is Watchman a key growth driver? - Management confirmed that Watchman is a significant growth driver, with expectations of continued market expansion and strong adoption rates [32][34] Question: What is the outlook for the China market? - Management indicated strong growth in China, with expectations for continued double-digit growth despite pricing pressures [39][40] Question: How will the new product cycle impact CRM growth? - Management expressed confidence in the upcoming Denali platform and Empower leadless pacemaker, anticipating improved growth in the CRM segment [85][86] Question: What are the drivers for growth outside EP and Watchman? - Management highlighted strong performance in neuromodulation, endoscopy, and the potential of the Nalu acquisition to enhance growth in the pain management segment [60][61]

Third quarter results just hitting from PepsiCo. Earnings there coming in at $229 a share. That was three cents ahead of estimates.Revenue coming in at $23.9% billion, also topping expectations. The company says that it now expects adjusted earnings to decline by about half a percent for the full year. That's an improvement from the prior guidance and better than Wall Street had anticipated.Pepsi also naming Steve Schmidt as the EVP and CFO. That's effective November 10th. Outgoing CFO Jamie Caulfield is go ...

Core Insights - PepsiCo, Inc. (PEP) is experiencing strong momentum in its PepsiCo Beverages North America (PBNA) division, which has achieved high-single-digit growth in away-from-home channels and gained market share in no-sugar colas and Gatorade sports drinks [2][9] - The Frito-Lay North America (FLNA) division is facing challenges in stabilizing volumes across its core snack portfolio, particularly with the Lay's brand, while making progress in subcategories like Cheetos and Doritos [3][4][9] - The overall performance of PepsiCo in Q3 2025 will depend on whether the strong growth in PBNA can offset the ongoing headwinds faced by FLNA [4] PepsiCo Beverages North America (PBNA) - PBNA has delivered high-single-digit growth in away-from-home channels and gained market share in no-sugar colas and Gatorade [2][9] - The division's focus on innovation, affordability, and functional hydration products is driving consumer demand [2][9] - Management believes that PBNA will remain a key growth driver in the latter half of 2025 [2] Frito-Lay North America (FLNA) - FLNA is struggling with volume stabilization, particularly in the potato chip segment and Lay's brand, while making progress in other snack categories [3][4][9] - The division is addressing challenges through relaunches that emphasize natural ingredients and "real food" positioning [3] - Management is rightsizing its manufacturing footprint and pursuing productivity savings, but excess capacity and workforce adjustments may impact near-term performance [3] Competitive Landscape - Compared to Coca-Cola (KO), which is heavily beverage-focused and has a more straightforward growth trajectory, PepsiCo faces challenges in its snacking business [5][6] - Mondelez International (MDLZ) benefits from strong pricing power in its snacking category, unlike PepsiCo's FLNA, which is currently under pressure [7] Stock Performance and Valuation - PepsiCo shares have gained 12.8% in the past three months, contrasting with a 0.5% decline in the industry [8] - The company trades at a forward price-to-earnings ratio of 17.89X, slightly below the industry average of 18.24X [10] - The Zacks Consensus Estimate for PepsiCo's 2025 earnings implies a year-over-year decline of 1.8%, while the 2026 estimate suggests a growth of 5.2% [11]

Core Insights - Medtronic plc reported its first quarter fiscal 2026 financial results, achieving mid-single digit organic revenue growth for the 11th consecutive quarter, with expectations to accelerate growth in the second half of the fiscal year [1][2][3] Financial Performance - The company reported worldwide revenue of $8.578 billion, an increase of 8.4% as reported and 4.8% on an organic basis [3][4] - GAAP operating profit was $1.445 billion with an operating margin of 16.8%, reflecting a 13% increase and a 70 basis point improvement [3][4] - Non-GAAP operating profit was $2.016 billion with a margin of 23.6%, showing a 3% increase but an 80 basis point decrease [3][4] Earnings and Guidance - GAAP net income was $1.040 billion, with diluted earnings per share (EPS) at $0.81, remaining flat, while non-GAAP diluted EPS increased by 2% to $1.26 [4][8] - The company raised its FY26 EPS guidance to a range of $5.60 to $5.66, up from the previous range of $5.50 to $5.60, and reiterated its organic revenue growth guidance of approximately 5% [7][8][9] Segment Performance - Cardiac Ablation Solutions revenue surged nearly 50%, with a 72% increase in the U.S. driven by pulsed field ablation products [4][5] - The Cardiovascular Portfolio generated $3.285 billion in revenue, a 9.3% increase as reported and 7.0% organic [5][19] - The Diabetes business reported revenue of $721 million, an increase of 11.5% as reported and 7.9% organic [5][19] International and U.S. Revenue - International revenue reached $4.354 billion, a 13.6% increase, while U.S. revenue was $4.224 billion, reflecting a 3.5% increase [22][19] - The Cardiovascular segment in the international market grew by 12.6%, with notable increases in Cardiac Rhythm & Heart Failure and Structural Heart & Aortic categories [22][19] Operational Efficiency - The company is focused on improving efficiencies in manufacturing, supply chain, and operating expenses to drive earnings growth while increasing investments in R&D, sales, and marketing [9][8]